Journal of Cystic Fibrosis

Journal Information
ISSN / EISSN : 1569-1993 / 1873-5010
Current Publisher: Elsevier BV (10.1016)
Total articles ≅ 10,168
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
Archived in
SHERPA/ROMEO
EBSCO
Filter:

Latest articles in this journal

Emrah Gecili, Weiji Su, Cole Brokamp, Eleni-Rosalina Andrinopoulou, Francis J. LaRosa III, Teresa Pestian, John P. Clancy, George M. Solomon, John J. Brewington,
Published: 1 May 2021
Journal of Cystic Fibrosis; doi:10.1016/j.jcf.2021.04.001

, Olga Archangelidi, , Darius Armstrong-James, Stuart J. Elborn, , Jane C. Davies
Published: 1 May 2021
Journal of Cystic Fibrosis; doi:10.1016/j.jcf.2021.04.007

The publisher has not yet granted permission to display this abstract.
, Ruth Watson, Wang Yng Lim, Kim Pollard, Christine Etherington, Ian J Clifton, Daniel G Peckham
Published: 1 April 2021
Journal of Cystic Fibrosis; doi:10.1016/j.jcf.2021.03.005

Abstract:
Background Exercise tolerance in people with CF and advanced lung disease is often reduced. While supplemental oxygen can improve oxygenation, it does not affect dyspnoea, fatigue or comfort. Nasal high-flow therapy (NHFT), thanks to its pathophysiological mechanisms, could improve exercise tolerance, saturation and dyspnoea. This study explores the feasibility of conducting a clinical trial of using NHFT in patients with CF during exercise. Methods A pilot, open-label, randomized crossover trial was performed, enroling 23 participants with CF and severe lung disease. Participants completed two treadmill walking test (TWT) with and without NHFT at 24–48 h interval. Primary outcome was trial feasibility, and exploratory outcomes were TWT distance (TWTD), SpO2, transcutaneous CO2, dyspnoea and comfort. Results Recruitment rate was 2.4 subjects/month with 1.3:1 screening-to-randomization ratio. No adverse events caused by NHFT were observed. Tolerability was good and data completion rate was 100%. Twenty subjects (91%) were included in the exploratory study. Mean difference in TWTD on NHFT was 19 m (95% CI [4.8 - 33.1]). SpO2 was similar, but respiratory rate and mean tcCO2 were lower on NHFT (mean difference = -3.9 breaths/min 95% CI [-5.9 - -1.9] and -0.22 kPa 95% CI [-0.4 – 0.04]). NHFT reduced exercise-induced dyspnoea and discomfort. Conclusion Trials using NHFT in patients with CF during exercise are feasible. NHFT appears to improve walking distance, control respiratory rate, CO2, dyspnoea and improve comfort. A larger trial with a longer intervention is feasible and warranted to confirm the impact of NHFT in training programmes for patients with CF.
, Chantal Darquenne, Daniël Schuermans, Sylvia Verbanck, Eef Vanderhelst
Published: 1 April 2021
Journal of Cystic Fibrosis; doi:10.1016/j.jcf.2021.03.016

The publisher has not yet granted permission to display this abstract.
, Mathias Declercq, Siham Bousfia, , Peter Witters
Published: 1 April 2021
Journal of Cystic Fibrosis; doi:10.1016/j.jcf.2021.03.019

The publisher has not yet granted permission to display this abstract.
Sneha Varkki, Antony Terance Benjamin, Rekha Athiyarath, Sumita Danda, Ravikumar Sowmya,
Published: 1 April 2021
Journal of Cystic Fibrosis; doi:10.1016/j.jcf.2021.03.023

, J.S. Elborn, S. Madge, L. Allen, M. Boeri, F. Kee, S. Goundry, T. Purcell, C. Saunders,
Published: 1 April 2021
Journal of Cystic Fibrosis; doi:10.1016/j.jcf.2021.03.021

The publisher has not yet granted permission to display this abstract.
, Gianfranco Alicandro, Mark Oliver, Peter J Lewindon, Grant A Ramm, Chee Y. Ooi, Federico Alghisi, , , Fabiola Corti, et al.
Published: 1 April 2021
Journal of Cystic Fibrosis; doi:10.1016/j.jcf.2021.03.014

The publisher has not yet granted permission to display this abstract.
Peter G Middleton
Published: 1 April 2021
Journal of Cystic Fibrosis; doi:10.1016/j.jcf.2021.03.020

Back to Top Top